Intranasal nalmefene - Opiant Pharmaceuticals

Drug Profile

Intranasal nalmefene - Opiant Pharmaceuticals

Alternative Names: OPNT-003

Latest Information Update: 01 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Opiant Pharmaceuticals
  • Developer National Institute on Drug Abuse; Opiant Pharmaceuticals
  • Class Antidotes; Hepatoprotectants; Morphinans; Neuroprotectants; Small molecules; Smoking cessation therapies
  • Mechanism of Action Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Opioid abuse

Most Recent Events

  • 01 Jun 2018 Chemical structure information added
  • 22 Feb 2018 Aegis Therapeutics has patent protection for fast acting nasal spray opioid blockers and pain medications in USA
  • 12 Feb 2018 Phase-I clinical trials in Opioid abuse in USA (Intranasal) before February 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top